Romark Alinia "approvable" for adults, approval for children
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Romark Labs' Alinia (nitazoxanide) tablet formulation is deemed "approvable" for adult patients 12 years and older Nov. 22. FDA clears the oral suspension for pediatric patients ages one to 11 years on the same day. The new molecular entity is indicated for treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia. Alinia is also pending at FDA for use in AIDS patients. Romark says the product will be available in February 200
You may also be interested in...
Romark Alinia Tab. Approval Expected First Half 2004; AIDS Claim To Follow
Romark expects approval in the first half of 2004 for a tablet formulation of its antimicrobial Alinia for use in immunocompetent adults and adolescents with diarrhea associated with Giardia lamblia and Cryptosporidium parvum.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.